AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8693937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified information activities
Number of subjects: 275
Study 8693937 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use at first intercourse
Number of subjects: 275
Study 8693937 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use when changing partner
Number of subjects: 275
Study 8693937 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about safety of oral contraceptives
Number of subjects: 275
Study 1883670 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 at 30 ng/kg/min
Number of subjects: 20
Study 1883670 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol at 5 ng/kg/min
Number of subjects: 20
Study 6129459 — intervention group
Group type: COMPARATOR
Intervention: fenoprofen
Number of subjects: 0
Study 6129459 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhus tox. 6X
Number of subjects: 0
Study 31653800 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum (QL) block
Number of subjects: 80
Study 31653800 — intervention group
Group type: COMPARATOR
Intervention: Control (no block)
Number of subjects: 80
Study 28127204 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM + vaccine
Number of subjects: 225
Study 28127204 — intervention group
Group type: COMPARATOR
Intervention: LAM + placebo
Number of subjects: 225
Study 26265560 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy with good adherence
Number of subjects: 73
Study 25493316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscope
Number of subjects: 381
Study 25493316 — intervention group
Group type: COMPARATOR
Intervention: Naked-eye examination (Control)
Number of subjects: 381
Study 22467697 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (n = 83)
Number of subjects: 160
Study 22467697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 77)
Number of subjects: 160
Study 19607951 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal vaccine (Inflexal V)
Number of subjects: 105
Study 19607951 — intervention group
Group type: COMPARATOR
Intervention: Standard subunit vaccine (Influvac)
Number of subjects: 105
Study 17542868 — intervention group
Group type: EXPERIMENTAL
Intervention: Go Sun Smart program
Number of subjects: 357
Study 17542868 — intervention group
Group type: COMPARATOR
Intervention: Control resorts
Number of subjects: 357
Study 15109968 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine iontophoresis
Number of subjects: 18
Study 15109968 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin-induced muscle pain
Number of subjects: 18
Study 15109968 — intervention group
Group type: COMPARATOR
Intervention: Saline iontophoresis (placebo)
Number of subjects: 18
Study 11233454 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-phased patient education program (RHYTHMS)
Number of subjects: 246
Study 11233454 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no educational materials)
Number of subjects: 246
Study 9686498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sarcoidosis (BAL fluid)
Number of subjects: 18
Study 9686498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sarcoidosis (Peripheral blood)
Number of subjects: 18
Study 9686498 — intervention group
Group type: COMPARATOR
Intervention: Control group (BAL fluid)
Number of subjects: 18
Study 9686498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sarcoidosis (BAL fluid vs Peripheral blood)
Number of subjects: 18
Study 7852064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group, 50 mg elemental iron + 60 mg ascorbic acid in a multi‐vitamin daily
Number of subjects: 128
Study 7852064 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-dose group, 200 mg elemental iron daily
Number of subjects: 128
Study 7852064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 7852064 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 128
Study 2682011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate solution plus 50 gm of albumin (group A)
Number of subjects: 100
Study 2682011 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution alone (group B)
Number of subjects: 100
Study 1253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparation containing 250 mg clofibrate and 180 mg inositol nicotinate
Number of subjects: 14
Study 1253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate alone in double doses
Number of subjects: 14
Study 1253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparation (doubled dose)
Number of subjects: 14
Study 1253701 — intervention group
Group type: COMPARATOR
Intervention: Clofibate alone
Number of subjects: 14
Study 1253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparation
Number of subjects: 14
Study 29258812 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg bevacizumab with FOLFIRI
Number of subjects: 124
Study 29258812 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 124
Study 26661514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 492
Study 26661514 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide 0.9 mg
Number of subjects: 492
Study 25827011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin included in complex intensive care (starting from 2 days post-traumatic period)
Number of subjects: 39
Study 25827011 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care
Number of subjects: 39
Study 22289674 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (H2RA) administered per os as a single dose immediately before surgery
Number of subjects: 18
Study 22289674 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI) administered in two oral doses (the night before and on the morning of surgery)
Number of subjects: 18
Study 22289674 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI) administered as a single intravenous infusion
Number of subjects: 18
Study 22289674 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists (H2RA) administered in two doses (the night before and on the morning of surgery)
Number of subjects: 18
Study 20809746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative knee adduction moment during gait
Number of subjects: 37
Study 20809746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of implant type, preoperative knee joint loading patterns during gait, and body mass index
Number of subjects: 37
Study 20809746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative functional characteristics
Number of subjects: 37
Study 19033601 — intervention group
Group type: EXPERIMENTAL
Intervention: G20 (20% maximal strength)
Number of subjects: 112
Study 19033601 — intervention group
Group type: EXPERIMENTAL
Intervention: G50 (50% maximal strength)
Number of subjects: 112
Study 19033601 — intervention group
Group type: EXPERIMENTAL
Intervention: G80 (80% maximal strength)
Number of subjects: 112
Study 19033601 — intervention group
Group type: COMPARATOR
Intervention: CON (nontraining control group)
Number of subjects: 112
Study 16575276 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction counselling
Number of subjects: 523
Study 16575276 — intervention group
Group type: COMPARATOR
Intervention: No counselling
Number of subjects: 523
Study 16575276 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional counselling strategy
Number of subjects: 523
Study 16575276 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselled patients
Number of subjects: 523
Study 16575276 — intervention group
Group type: COMPARATOR
Intervention: Not counselled patients
Number of subjects: 523
Study 12874608 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (n=1899)
Number of subjects: 2202
Study 12874608 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan in combination with hydrochlorothiazide (n=276)
Number of subjects: 2202
Study 12874608 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control group, n=27)
Number of subjects: 2202
Study 10984366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 microg/actuation) plus salbutamol (100 microg/actuation) administered as 4 puffs every 20 minutes for 3 doses.
Number of subjects: 74
Study 10984366 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 microg/actuation) alone administered as 4 puffs every 20 minutes for 3 doses.
Number of subjects: 74
Study 8560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg/day for 12 weeks
Number of subjects: 0
Study 8560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 100-200 mg/day
Number of subjects: 0
Study 8560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide up to 450 mg daily
Number of subjects: 0
Study 1832346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianette + 2 mg CPA
Number of subjects: 60
Study 1832346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianette + 20 mg CPA
Number of subjects: 60
Study 1832346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianette + 100 mg CPA
Number of subjects: 60
Study 6418109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate addition
Number of subjects: 39
Study 6418109 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate addition in amitriptyline-pretreated patients
Number of subjects: 39
Study 6418109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate withdrawal
Number of subjects: 39
Study 30617197 — intervention group
Group type: EXPERIMENTAL
Intervention: obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy
Number of subjects: 1418
Study 30617197 — intervention group
Group type: EXPERIMENTAL
Intervention: activated B-cell-like (ABC) COO subtype
Number of subjects: 1418
Study 30617197 — intervention group
Group type: EXPERIMENTAL
Intervention: unclassified COO subtype
Number of subjects: 1418
Study 30617197 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-IPI-C model (high CNS-IPI and ABC/unclassified COO)
Number of subjects: 1418
Study 30239561 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3OHB) infusion
Number of subjects: 10
Study 30239561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonesterified fatty acids (Intralipid) infusion
Number of subjects: 10
Study 30239561 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study 26991329 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min plasma glucose (30-min PG) tertiles: T1 < 9.1 mmol/L, T2 9.2-10.4 mmol/L, T3 ≥ 10.4 mmol/L
Number of subjects: 753
Study 26991329 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min plasma glucose (30-min PG)
Number of subjects: 753
Study 24913484 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (500 ml containing 160 mg of caffeine)
Number of subjects: 15
Study 24913484 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink + Rest (500 ml of energy drink and 10 min rest after 100 min of driving)
Number of subjects: 15
Study 24913484 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (500 ml)
Number of subjects: 15
Study 22301126 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg
Number of subjects: 373
Study 22301126 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg
Number of subjects: 373
Study 22301126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 20467003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 26
Study 20467003 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 26
Study 18047036 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 0
Study 18047036 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15735265 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant warmer (Fisher & Paykel)
Number of subjects: 8
Study 15735265 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warmer (Augustine Medical)
Number of subjects: 8
Study 15735265 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester filled blanket
Number of subjects: 8
Study 11880561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat consumption (14 g/d of dietary fiber, 5.5 g beta-glucan)
Number of subjects: 36
Study 11880561 — intervention group
Group type: COMPARATOR
Intervention: Wheat cereals (14 g/d of dietary fiber, no beta-glucan)
Number of subjects: 36
Study 10193912 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 191
Study 10193912 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 191
Study 8566890 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-donor fresh frozen plasma (FFP) substitution, total of 42 doses at a median of 10 (5-20) mliter/kg.
Number of subjects: 42
Study 2278982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient family intervention (IFI) added to medication during the inpatient phase of treatment.
Number of subjects: 0
Study 2278982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient family intervention (IFI)
Number of subjects: 0
Study 7193668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dalacin C and Spectacilline for five days postoperatively
Number of subjects: 54
Study 7193668 — intervention group
Group type: COMPARATOR
Intervention: Taurolin administered by intraperitoneal route
Number of subjects: 54
Study 31792863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received normal care plus HCV antibody tests ordered and customized messages sent through their tPHR inviting them to go directly to the lab for HCV screening over a 12-week period.
Number of subjects: 1024
Study 31792863 — intervention group
Group type: COMPARATOR
Intervention: Control group received normal care for HCV screening, consisting of passive HCV reminders to providers and passive HCV screening notification through the patient's tPHR.
Number of subjects: 1024
Study 31190609 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily
Number of subjects: 420
Study 31190609 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of pravastatin daily
Number of subjects: 420
Study 31190609 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (both atorvastatin and pravastatin)
Number of subjects: 420
Study 31190609 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 420
Study 28931088 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nutrition and health program
Number of subjects: 957
Study 28931088 — intervention group
Group type: COMPARATOR
Intervention: Comparison district (Government of India's standard nutrition and health care program)
Number of subjects: 957
Study 25579414 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS to visual cortex
Number of subjects: 23
Study 25579414 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 23
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III anti‐arrhythmic drugs at baseline
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis at baseline and 1 year
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti‐coagulation (OAC) without anti‐platelet drugs
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conversions
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical conversions
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisations
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: Strokes
Number of subjects: 2742
Study 23979564 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc scores
Number of subjects: 2742
Study 21131556 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-641988 (daily doses escalated from 5 to 150 mg)
Number of subjects: 61
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAC pain score
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-m walk test
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairs up test
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairs down test
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT extension of the affected side
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT flexion of the affected side
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT flexion of the contralateral side
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND-36 Physical function (PF) score
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid diseases and pain
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 88
Study 18608423 — intervention group
Group type: EXPERIMENTAL
Intervention: Malalignments, restriction in flexion ROM, and radiologic severity of knee OA
Number of subjects: 88
Study 16772904 — intervention group
Group type: EXPERIMENTAL
Intervention: Innervated flap (12 patients, 18 breasts)
Number of subjects: 27
Study 16772904 — intervention group
Group type: COMPARATOR
Intervention: Noninnervated flap (15 patients, 19 breasts)
Number of subjects: 27
Study 15588464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg on stimulation day 7 with r-hLH 150 IU on days 7-10 (n = 25)
Number of subjects: 74
Study 15588464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 3 mg on stimulation day 7 without r-hLH on days 7-10 (n = 24)
Number of subjects: 74
Study 15588464 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate before ovarian stimulation with r-hFSH (n = 25)
Number of subjects: 74
Study 11232016 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) and norethisterone enanthate (NETE)
Number of subjects: 28
Study 11232016 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) alone
Number of subjects: 28
Study 9207711 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects (mean, 2.01 ± 0.46 degrees)
Number of subjects: 40
Study 9207711 — intervention group
Group type: EXPERIMENTAL
Intervention: Active elderly subjects (mean, 3.12 ± 1.12 degrees)
Number of subjects: 40
Study 8480477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms beclomethasone
Number of subjects: 15
Study 8480477 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms beclomethasone
Number of subjects: 15
Study 8480477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3103044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 12
Study 3103044 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 12
Study 29443445 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin withdrawal
Number of subjects: 22
Study 29443445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28390213 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik® Water Flosser (WF) plus manual tooth brushing
Number of subjects: 28
Study 28390213 — intervention group
Group type: COMPARATOR
Intervention: Interdental brushes (IDB) plus manual tooth brushing
Number of subjects: 28
Study 24484241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 83
Study 24484241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 22425883 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxcinod
Number of subjects: 349
Study 22425883 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 349
Study 22425883 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 349
Study 22425883 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxcinod, Naproxen, Ibuprofen
Number of subjects: 349
Study 19702662 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal intervention designed to reduce depressive symptoms, implemented over a 3-year period, including a comprehensive classroom curriculum programme, enhancements to the school climate, improvements in care pathways, and community forums.
Number of subjects: 5634
Study 19702662 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 5634
Study 19702662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (staff-rated assessments of school climate)
Number of subjects: 5634
Study 19090319 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received five 15-minute bright light pulses during night shifts, wore dark sunglasses outside, slept in dark bedrooms, and received outdoor afternoon light exposure.
Number of subjects: 24
Study 19090319 — intervention group
Group type: COMPARATOR
Intervention: Control group remained in normal room light during night shifts, wore lighter sunglasses, and had unrestricted sleep and outdoor light exposure.
Number of subjects: 24
Study 16911871 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT (home-based)
Number of subjects: 119
Study 16911871 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAT (group-based)
Number of subjects: 119
Study 12820071 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally supportive care (DSC) training program
Number of subjects: 25
Study 12820071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DSC training)
Number of subjects: 25
Study 11256825 — intervention group
Group type: EXPERIMENTAL
Intervention: Revien and Gabor's Sports Vision programme (Group 1)
Number of subjects: 40
Study 11256825 — intervention group
Group type: EXPERIMENTAL
Intervention: Revien's Eyerobics (Group 2)
Number of subjects: 40
Study 11256825 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition involving reading (Group 3)
Number of subjects: 40
Study 11256825 — intervention group
Group type: COMPARATOR
Intervention: Control condition involving physical practice only (Group 4)
Number of subjects: 40